Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2015 | Data on new therapeutic strategies in Hodgkin lymphoma

Andrew Davies • 12 Jun 2015
EHA 2015
Hodgkin Lymphoma

Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the University of Southampton, Southampton, UK, provides an update on clinical trial data in new treatments for Hodgkin lymphoma (HL) presented at the 20th Congress of the European Hematology Association (EHA).

Topics of interest include bendamustine-containing regimen (BeGEV) as induction chemotherapy prior to autologous stem cell transplantation for patients with relapsed or refractory HL and the phase 1 trial of doxorubicin, vinblastine, dacarbazine, and lenalidomide (AVD-Rev) for elderly patients with HL.

More from Andrew Davies

Novel therapies in NHL: antibody-drug conjugates
Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023
Economic burden of CAR-T therapy from a UK perspective
1:11
Economic burden of CAR-T therapy from a UK perspective
Andrew Davies • 24 Apr 2023
Primary analysis of the Phase III TRANSFORM study: liso-cel in second-line LBCL
2:40
Primary analysis of the Phase III TRANSFORM study: liso-cel in second-line LBCL
Andrew Davies • 24 Apr 2023
REMoDL-B: bortezomib + R-CHOP versus R-CHOP in patients with DLBCL
1:44
REMoDL-B: bortezomib + R-CHOP versus R-CHOP in patients with DLBCL
Andrew Davies • 24 Apr 2023

Related Videos

Selecting frontline therapy with BV-AVD or nivolumab plus AVD in Hodgkin lymphoma
1:16
Selecting frontline therapy with BV-AVD or nivolumab plus AVD in Hodgkin lymphoma
Stephen Ansell • 11 Sep 2026
Balancing efficacy and long-term toxicity in frontline Hodgkin lymphoma
1:10
Balancing efficacy and long-term toxicity in frontline Hodgkin lymphoma
Stephen Ansell • 11 Sep 2026
Advice for community oncologists on managing patients with HL: when to refer to a specialist center
1:42
Advice for community oncologists on managing patients with HL: when to refer to a specialist center
Cathy Burton • 6 Jul 2026
UK insights into how brentuximab vedotin and PD-1 inhibitors are currently sequenced for relapsed HL
2:36
UK insights into how brentuximab vedotin and PD-1 inhibitors are currently sequenced for relapsed HL
Cathy Burton • 14 Jun 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals